CVS Caremark names EVP specialty pharmacy
WOONSOCKET, R.I. — CVS Caremark announced on Thursday the appointment of Alan Lotvin to the position of EVP specialty pharmacy.
Lotvin has extensive experience in the pharmacy benefit management and specialty pharmacy industries. Prior to joining CVS Caremark, Lotvin was president and CEO of Icore Healthcare, a Magellan Health Services company. Previously, he has held roles as president and COO of M|C Communications, a medical education provider, and served in various senior management positions at Medco Health Solutions, including president of specialty pharmacy services.
"Specialty pharmacy is an increasingly important growth area for CVS Caremark, and Alan’s in-depth experience and knowledge of the industry make him uniquely qualified to lead this portion of our business," said Jon Roberts, president of the CVS Caremark PBM business. "His expertise will enable us to continue to grow our specialty pharmacy leadership and identify opportunities for ongoing innovation to enable us to better help patients dealing with complex, debilitating diseases."
"I am looking forward to working with the team at CVS Caremark to continue to grow and build upon the company’s specialty pharmacy offerings," Lotvin stated. "With specialty drugs estimated to account for seven of the top 10 drugs in the United States by 2016, we need to continue to develop programs and solutions that will help our clients improve outcomes for these complicated diseases while managing cost and ensuring appropriate utilization."
FDA approves first drug for eye condition
SILVER SPRING, Md. — The Food and Drug Administration has approved what it called the first drug to treat an eye condition that can interfere with the part of the retina responsible for reading vision.
The agency announced the approval of Jetrea (ocriplasmin), made by Iselin, N.J.-based ThromboGenics. The drug is used to treat symptomatic vitreomacular adhesion.
VMA contributes to eye problems if the vitreous, the jelly in the center of the eye, moves away from the macula, the part responsible for reading vision, leading to damage to the macula due to tugging or pulling.
Jetrea is an enzyme that breaks down proteins in the eye responsible for VMA, allowing better separation between the vitreous and macula and reducing the chances that tugging will occur, the FDA said.
FDA approves generic Lupin contraceptive
MUMBAI, India — The Food and Drug Administration has approved a generic contraceptive made by Indian drug maker Lupin, the company said Thursday.
Lupin announced the approval of Kurvelo (levonorgestrel and ethinyl estradiol) tablets in the 0.15 mg/0.03 mg strength.
The drug is a generic version of Teva’s branded Nordette. Nordette had sales of about $59 million during the 12-month period ended in June, according to IMS Health.